Every Brand with a Lab Coat in Their Ads Uses This Word
The average American woman spends roughly $300 to $500 a year on skincare. The average product she buys sits on the outermost layer of her skin — the stratum corneum — which is made of dead cells. It moisturises temporarily, perhaps, or diffuses light with a bit of mica. It does not meaningfully change anything.
Yet most of these products carry a word that sounds clinical, scientific, and substantive: cosmeceutical. It appears on bottles at the drugstore and on counters at luxury retailers. It implies a higher standard, a pharmaceutical pedigree, a product that does more than sit prettily on the surface of your skin.
Here is what the word actually means: nothing legally definable. The FDA does not recognise the category. Any brand can use the term tomorrow. And most do.
The Word That Escaped Definition
The term "cosmeceutical" was coined in 1984 by Dr. Albert Kligman, a University of Pennsylvania dermatologist, to describe a product that sat somewhere between a cosmetic and a drug — something formulated to affect skin function rather than just appearance. It was never a regulatory category. It was a descriptive concept, born from the observation that some products clearly did more than cosmetics but less than prescription drugs, and there was no name for what they were.
There still isn't. The FDA recognises exactly two categories: cosmetics and drugs. Cosmetics are defined by what they do not claim — they "cleanse, beautify, promote attractiveness, or alter the appearance" without affecting the structure or function of the body. Drugs are defined by intent — they are intended to "affect the structure or function of the body" and must undergo rigorous pre-market approval. There is no third door.
The result is a regulatory gap that the beauty industry has driven through with considerable enthusiasm. A product containing retinol can be labelled "reduces the appearance of wrinkles" and regulated as a cosmetic, or "reduces wrinkles" and regulated as a drug. Same ingredient. Same concentration. Different claim. Different legal standard. And either way, the word "cosmeceutical" can appear on the bottle.
A $300 cream and a $40 drugstore serum can both legally call themselves cosmeceuticals tomorrow morning. The word itself carries no weight. What matters is whether the formulation behind it can.
What a Real Cosmeceutical Does That a Cosmetic Cannot
If the label is meaningless, what actually distinguishes a product that performs at a cosmeceutical level from one that simply markets itself that way? The answer comes down to three things — and none of them appear on the front of the bottle.
What it changes in the skin. A conventional cosmetic alters appearance temporarily. It hydrates the outer layer of the stratum corneum. It fills fine lines with film-forming polymers that create a temporary smoothing effect. It diffuses light with mineral particles. These are all legitimate functions, and they are what the cosmetic regulatory framework was designed to accommodate.
A genuine cosmeceutical is formulated to do something fundamentally different: to affect how skin cells behave at a biological level. To signal fibroblasts to produce collagen. To inhibit the enzymatic pathway that produces melanin. To modulate neurotransmitter release at the neuromuscular junction where expression lines form. The Beautiful With Brains article describes cosmeceutical ingredients as "little messengers whispering directions to your skin cells" — an imperfect analogy but an accurate one for the direction of the mechanism. These products are not attempting to decorate the surface. They are formulated to communicate with living tissue.
This distinction matters because it changes what the formula must achieve. Decoration requires only surface deposition. Biological communication requires delivery to the right depth, at the right concentration, in a vehicle that the skin's own biology recognises as compatible.
How deep it reaches. The stratum corneum is roughly 15 to 30 layers of dead cells thick. It is the skin's primary barrier, evolved specifically to keep external substances out. Most conventional cosmetic ingredients are formulated with relatively large molecules that cannot cross this barrier in any meaningful quantity. They rest on the surface. They hydrate. They smooth. They do not reach the living layers below.
Below the stratum corneum is the viable epidermis — the layer where cell division occurs, where melanocytes produce pigment, where fibroblasts build collagen. A cosmeceutical must overcome the barrier to reach this layer. Common approaches include using smaller molecular weight versions of active ingredients (which can pass through the lipid matrix between corneocytes), encapsulation in liposomes or phospholipid carriers (which the skin recognises as biocompatible and allows through), and pH optimisation (which works with the skin's acid mantle rather than against it). These are not marketing features. They are engineering requirements for a product that claims to do more than sit on the skin.
Research supports that molecular weight reduction and delivery vehicle design can meaningfully influence how deeply an ingredient penetrates. It is equally true that many products claiming enhanced penetration do not actually achieve it. The difference between a formulation that reaches the viable epidermis and one that does not is not visible in the ingredient list. It is determined by how the ingredients are delivered — and that requires formulation expertise, not just a declaration on a label.
At what concentration. This may be the most consequential difference, and the one most obscured by current labelling practices. Many cosmetics list active ingredients on their labels at concentrations that are well below the threshold required for a measurable cellular response. A 2023 analysis in the Journal of Cosmetic Dermatology found that 40% of products labelled as "cosmeceutical" contained active ingredients at concentrations below levels shown effective in clinical trials. This is not always accidental. Formulating below the therapeutic threshold carries advantages: it avoids the stability challenges of maintaining high-concentration actives, it reduces production costs, and in some cases, it keeps a product safely within cosmetic classification — avoiding the regulatory obligations that come with drug-level claims.
A genuine cosmeceutical is formulated at a concentration where the active ingredient can produce the effect it claims. Achieving this concentration in a stable formula that remains effective over months of shelf life is harder than adding an ingredient at a label-listing level. It requires stabilisers that do not conflict with the active, packaging that protects against oxidation, and quality control that ensures every batch meets the same specification.
The mechanism that ties all three of these together is often pH. The skin's acid mantle operates at a pH of approximately 4.5 to 5.5. A formula calibrated to work within this range enhances the penetration of active ingredients while protecting the barrier's integrity. A formula that ignores pH can damage the barrier, cause irritation, or render its own active ingredients ineffective. This calibration — understanding how each ingredient behaves at different pH levels, how the delivery vehicle interacts with the skin's natural charge, and how the formula changes as it dries on the skin — is chemistry. Not marketing.
Building a product that does all three of these things correctly requires chemistry. It cannot be accomplished by selecting ingredients from a catalogue and blending them into a base cream. It cannot be accelerated by skipping stability testing. And it cannot be faked by adding a lab coat to the product photography.
How Do You Know Which Brands Are the Real Ones?
That question has one honest answer: look at who built it and what they built it with.
Dr. Volynsky holds a PhD in organic chemistry. When she looks at a formula, she sees molecular architecture — whether the active ingredient is stable at its intended concentration, whether the delivery vehicle can carry it to the depth where it needs to act, whether the supporting ingredients will maintain that stability over months of shelf life. These are not things a marketing team sees. They are things a chemist with 25 years of formulation experience sees. She co-founded the Cosmoceutical Research Center in 1995 with Dr. Vartan Libaridian.
Dr. Libaridian holds a PhD in pharmaceuticals and is a registered pharmacist. He spent years as technical director at Neutrogena. His expertise is in transdermal delivery — the same principles used in pharmaceutical patches that deliver medication through the skin, applied here to cosmeceutical ingredients. A pharmacist understands something that a cosmetic formulator alone may not: that the vehicle carrying the active ingredient determines its efficacy as much as the ingredient itself. His background changes what the lab builds.
The convergence of these two specialisations — organic chemistry and pharmaceutical delivery — is genuinely rare in skincare. Most brands have one formulator. Many have none at all, relying instead on contract manufacturers who build from a catalogue of pre-made bases. Nujevi was founded by two scientists who each brought a distinct discipline to the same question: how do you get an active ingredient to the right place at the right concentration in a stable, certifiable formula?
The question took a patent to answer. United States Patent 8,460,687 B1 was granted on June 11, 2013, covering peeling compositions based on phytic acid — a natural antioxidant derived from rice bran — for skin resurfacing, hyperpigmentation, and related applications. The patent process requires proving to a federal body that the formulation is novel, non-obvious, and genuinely different from everything that came before. Federal examiners review the prior art across the entire field. They found nothing comparable. The only other company holding the same patent classification? Johnson & Johnson.
By 2010, the industry had started to notice. Forbes ran a feature on the technology — a deep chemical peel that achieved professional results without the standard risks of scarring, infection, and general anaesthesia. The article noted that the formulation "has eliminated the intense inflammation, swelling, and blistering associated with other deep peels," allowing patients to "immediately return to work and achieve dramatic rejuvenation within a week." The recognition followed results, not press releases.
The manufacturing facility is FDA-registered for both cosmetics and drug-licensed production. It is Oregon Tilth certified — one of the strictest organic certifications in the United States — and achieving that certification at therapeutic active concentrations is genuinely difficult. Most organic-certified brands use lower active concentrations because high-concentration actives require different sourcing, extraction, and stabilisation methods that most organic certifiers will not approve. Nujevi maintained both: therapeutic concentrations and full certification.
The Honest Warning
Cosmeceuticals are not for everyone. A product formulated at a therapeutic concentration is more potent than a conventional cosmetic, and potency carries risk if misused. This is not a warning to be inserted and then walked back with reassurances. It is a genuine constraint on who should use these products and under what conditions.
If your skin barrier is compromised — from over-exfoliation, untreated inflammatory conditions, or aggressive treatments — applying high-concentration actives can worsen the problem rather than help it. A compromised barrier lacks the defence mechanisms that healthy skin has, and active ingredients that perform well on intact skin can penetrate too deeply or too quickly through compromised tissue. This is why dermatologists recommend repairing the barrier before introducing therapeutic-level actives.
Results require consistency. One full skin cell turnover cycle takes a minimum of 28 days. Visible structural changes — increased collagen density, improved elasticity, reduced pigmentation — require multiple cycles. The clinical literature on retinol, for example, shows that meaningful improvements in skin texture and collagen density require 12 to 24 weeks of consistent use. A product used sporadically, or abandoned after two weeks because visible results had not yet appeared, will not produce the outcome its formulation is capable of delivering. This is not a flaw in the product. It is a function of the rate at which human skin renews itself.
A 2017 study published in JAMA Dermatology examined 187 anti-aging products sold by major US retailers. Only 11 of them — less than 6% — had at least one published study supporting their efficacy claims that met basic methodological criteria. This does not mean the other 176 products were useless. It does mean that most of them had never been tested in a way that would allow a consumer to know whether they worked. The problem with the cosmeceutical category is not just that the label is unregulated. It is that most products carrying the label have never been asked to prove anything.
Layering multiple active products without understanding their interactions can cause damage. Two well-formulated products can conflict at the pH level, compete for the same delivery pathway, or collectively exceed the skin's tolerance threshold. The Environmental Working Group reports that the average American woman uses 12 personal care products daily, containing approximately 168 unique chemical ingredients. Not all of those ingredients are problematic. But the probability that 168 ingredients across 12 products interact well together approaches zero without deliberate formulation design. A simplified routine using fewer, better-formulated products — used consistently — almost always outperforms a complex routine built from ingredients that may be working against each other.
The Routine Reality
Because genuine cosmeceuticals are formulated to reach living skin at effective concentrations, they do not require a twelve-product routine to produce results. A well-designed regimen of three or four formulations — each engineered for depth, concentration, and pH compatibility — can address what a cabinet full of conventional products cannot. This is not a simplification for convenience. It is the logical consequence of formulations that actually reach the layer where skin change happens.
This is also why the price point exists. A formula built around a therapeutic concentration of a peptide, delivered through a phospholipid carrier, in an organic-certified base that has been stability-tested over years, is more expensive to produce than a formula that simply lists the ingredient at a decorative level. The question is not whether it costs more. It does. The question is whether the cost reflects real formulation investment or marketing spend.
The Close
Most people will read this, nod, and buy the same products they were already planning to buy. That is fine. The beauty industry is built on that decision, and it is not a bad one.
But if you are at the point where you want to understand your skin rather than decorate it — where you are interested in what actually happens in the living layers where collagen is built and pigment is controlled — then the question is not which moisturizer to buy. It is whether what you are using was built by people who understand that layer at all.
Dr. Volynsky does. That is why she built Nujevi.
This article is part of Doctor's Notes, the MD Cosmetique blog where we publish honest science about what goes on your skin. Read more from Doctor's Notes, or learn about the founders and their history.
The full science behind cosmeceuticals
About Dr. Volynsky and Dr. Libaridian
